Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Novel treatment-specific causal biomarkers for colorectal cancer by omics integration

NAR Genomics and Bioinformatics(2025)10.1093/nargab/lqaf053Source: DataRank Database

Novel treatment-specific causal biomarkers for colorectal cancer by omics integration is a research paper published in NAR Genomics and Bioinformatics (2025). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Download PDF

Cite:

Linked data & code

geo doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (10 grants)Impact (FWCI 0.00)OA: goldTopics (40)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (14)

Azam Yazdani,Raúl Méndez-Giráldez ORCID,Gianluigi Pillonetto ORCID,Esmat Samiei,Reza Hadi

Live enrichment

PubMed:40585306 PMC:PMC12204401 OpenAlex:https://openalex.org/W4411718141

NCI

Grant: U10CA180821

NCI

Grant: U10CA180882

NCI

Grant: U24CA196171

National Institutes of Health

Grant: 5U10CA180882-02

Statistics and Data Center for the Alliance for Clinical Trials in Oncology

National Institutes of Health

Grant: 3U24CA196171-04S1

THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCE

National Institutes of Health

Grant: 3U10CA180821-02S2

Alliance for Clinical Trials in Oncology Operations Center

Genentech

Sanofi

Bristol-Myers Squibb

Pfizer

FWCI

0.00

Citation Percentile

0.2%

goldLicense: cc-by

journalhttps://academic.oup.com/nargab/article-pdf/7/2/lqaf053/63526385/lqaf053.pdf

GOLDhttps://academic.oup.com/nargab/article-pdf/7/2/lqaf053/63526385/lqaf053.pdf

publisherhttps://academic.oup.com/nargab/article-pdf/7/2/lqaf053/63526385/lqaf053.pdf

journalhttps://doi.org/10.1093/nargab/lqaf053

repositoryhttps://pubmed.ncbi.nlm.nih.gov/40585306

Fields of Study

Colorectal Cancer Treatments and StudiesGenetic factors in colorectal cancerColorectal Cancer Screening and DetectionMedicineBiology03 medical and health sciences0302 clinical medicine

MeSH Terms

BevacizumabCetuximabAntineoplastic Agents, ImmunologicalFemaleHumansMaleBiomarkers, TumorColorectal NeoplasmsGene Expression Regulation, Neoplastic

Keywords

CetuximabColorectal cancerMedicineOncologyCancerCohortBevacizumabBiomarkerInternal medicineOmicsBioinformaticsPrecision medicineBiologyPathologyChemotherapyGeneticsMaleGene Expression Regulation, NeoplasticAntineoplastic Agents, ImmunologicalBiomarkers, TumorHumansFemaleStandard ArticleColorectal Neoplasms

Sustainable Development Goals

SDG 0: Good health and well-being